Genomic Health To Present Results On Oncotype DX Prostate Cancer Test

Genomic Health To Present Results On Oncotype DX Prostate Cancer Test
shutterstock_216989209Genomic Health, Inc. has announced it will present several studies during the 2014 Society of Urologic Oncology (SUO) Annual Meeting, including the second clinical validation study of the Oncotype DX prostate cancer test. Oncotype DX Prostate Cancer Assay is a genomic test performed on a patient’s needle biopsy and provides essential information regarding the biology of a patient’s prostate cancer. The results are reported as the Genomic Prostate Score or GPS, and provide a more precise, accurate, and individualized risk assessment, to help the patient and his physician decide between active surveillance and immediate treatment. The GPS works in conjunction with standard guidelines to determine prostate cancer risk, from very low to intermediate. Within each of these risk groups, the lower the GPS, the more favorable tumor biology, and the less likely it is for a patient to begin immediate treatment with surgery or radiation. The results to be presented are the latest in the validation of this test, and were developed together with the Center for Prostate Disease Research. Importantly, the study has been accepted for publication in the peer-reviewed journal European Urology. Additionally, the results of the decision impact study of Oncotype DX developed together with Columb
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *